Close
Blog & Resources Camargo Blog June 9th, 2011

Patent Cliff Causes Pfizer Cuts

Yesterday (08Jun11) The Wall Street Journal reported (subscription may be required) that Pfizer will cut an additional $1 Billion – mostly in administrative costs. These cuts come after cuts to sales and R&D. What’s driving all of these cuts is two-fold: loss of sales of their products to generics and failure to obtain approval for new drugs.

The pharmaceutical industry has known for some time that there is a looming patent cliff. As big pharma is not getting new drugs approved, there are fewer drugs to come off patent. See the WSJ chart below. These latter drugs are the feedstock for generic companies. Thus, generic companies also need to adjust their business costs or perhaps they should look at 505(b)(2) as the new business model.



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101, Mill No. 1
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights